azd5718
Small moleculeexperimental
Clinical trial activity
12 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02632526)
Timeline
Indications
Mechanism of action
- 5-lipoxygenase activating proteinINHIBITOR
ALOX5AP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd5718
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05251259 | Phase 2 | Jan 27, 2022 | AstraZeneca |
| NCT04734275 | Phase 1 | Feb 1, 2021 | AstraZeneca, Parexel |
| NCT04601467 | Phase 2 | Jan 1, 2021 | AstraZeneca, Government of Singapore, National University of Singapore |
| NCT04492722 | Phase 2 | Oct 1, 2020 | AstraZeneca, George Clinical Pty Ltd, Parexel, University of Groningen |
| NCT04492709 | Phase 1 | Jul 30, 2020 | AstraZeneca, Parexel |
| NCT04210388 | Phase 1 | Jan 13, 2020 | AstraZeneca, Parexel |
| NCT03948451 | Phase 1 | Apr 30, 2019 | AstraZeneca, Quotient |
| NCT03420092 | Phase 1 | Feb 5, 2018 | AstraZeneca, Parexel |
| NCT03400488 | Phase 1 | Jan 16, 2018 | AstraZeneca, Parexel |
| NCT03317002 | Phase 2 | Oct 31, 2017 | AstraZeneca |
| NCT02963116 | Phase 1 | Dec 20, 2016 | AstraZeneca, Parexel |
| NCT02632526 | Phase 1 | Feb 1, 2016 | AstraZeneca, Parexel |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 12 | 11 | 2 | 2016 |
| Parexel | For profit | 8 | 0 | 2 | 2016 |
| George Clinical Pty Ltd | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Government of Singapore | Government | 1 | 0 | 1 | 2021 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Quotient | For profit | 1 | 0 | 1 | 2019 |
| University of Groningen | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1